Tekla Capital Management’s Precision BioSciences DTIL Stock Holding History

Tekla Capital Management’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$118K	Hold	7,484	–	–	﹤0.01%	156
2023 Q1	$169K	Hold	7,484	–	–	0.01%	167
2022 Q4	$267K	Hold	7,484	–	–	0.01%	158
2022 Q3	$292K	Hold	7,484	–	–	0.01%	156
2022 Q2	$359K	Hold	7,484	–	–	0.01%	159
2022 Q1	$692K	Hold	7,484	–	–	0.02%	152
2021 Q4	$1.66M	Buy	7,484 +5,384	+256%	+$1.5M	0.05%	131
2021 Q3	$727K	Hold	2,100	–	–	0.02%	156
2021 Q2	$789K	Hold	2,100	–	–	0.03%	175
2021 Q1	$652K	Buy	+2,100	New	+$735K	0.02%	186

Other funds holding DTIL

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Tekla Capital Management's DTIL Position: Q2 2023 in Review

Tekla Capital Management held its Precision BioSciences (DTIL) position steady in Q2 2023 at 7,484 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #156.

Tekla Capital Management first reported a position in DTIL in Q1 2021 and has held it in 10 quarters since. The position peaked at $1.66M in Q4 2021. 77 funds tracked by Wall St. Rank hold DTIL as of Q2 2023.

Tekla Capital Management held 7,484 shares of Precision BioSciences worth $118K as of Q2 2023.
Tekla Capital Management left its Precision BioSciences share count unchanged in Q2 2023.
Precision BioSciences made up ﹤0.01% of Tekla Capital Management's portfolio in Q2 2023, its #156 holding.
Tekla Capital Management first reported a position in Precision BioSciences in Q1 2021 and has held it in 10 quarters since.
Tekla Capital Management's Precision BioSciences position peaked at $1.66M in Q4 2021.
77 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.